Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
12 hours ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Morgan Stanley’s Wilson: Bond Rout Threatens AI-Driven Stock Rally — But 12-Month Target Raised to 8,300

by Team Lumida
12 hours ago
Morgan Stanley Q2 2024 Earnings Summary

Morgan Stanley's Mike Wilson warns a bond market correction could trigger the first meaningful equity pullback since late March — while simultaneously raising his 12-month S&P 500 target...

Read more

OpenAI CFO: We’re Going Up a Vertical Wall of Demand — and May Raise Again

by Team Lumida
4 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI CFO Sarah Friar says the company — now at 900 million weekly ChatGPT users — may raise additional capital beyond its record $122 billion round as a...

Read more

xAI Is Pitching Grok to Wall Street — But Bankers Aren’t Biting Yet

by Team Lumida
4 days ago
xAI Is Pitching Grok to Wall Street — But Bankers Aren’t Biting Yet

Elon Musk's xAI has recruited Apollo, Morgan Stanley, and Valor to test Grok ahead of SpaceX's IPO, but the chatbot still lags behind Anthropic's Claude for finance use...

Read more

Fanuc Hits Record High After Google Partnership Signals Physical AI’s Next Frontier

by Team Lumida
4 days ago
Google’s Bold AI Bet: Transforming Healthcare After Costly Missteps

Shares of Fanuc, the world's largest robot arm maker, surged 16% to an all-time high after announcing a partnership with Google to build AI systems for industrial robots...

Read more

Anthropic In Talks to Raise $30 Billion at a $900 Billion Valuation

by Team Lumida
6 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic is in early discussions for what could be its largest fundraise yet, at a valuation that would make it one of the most valuable private companies in...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
6 days ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

Grok Is Losing the AI Race — and SpaceX Just Rented Its Best Data Center to Anthropic

by Team Lumida
7 days ago
Tesla Shareholders Revolt: Suing Elon Musk Over Competing AI Venture

Grok downloads have collapsed 60% from their January peak, enterprise adoption is nearly flat, and SpaceX is now renting its Colossus data center to rival Anthropic for a...

Read more

South Korea Floats ‘AI Dividend’ for Citizens — Sparking a 5% Market Plunge Before Clarification

by Team Lumida
7 days ago
South Korea Floats ‘AI Dividend’ for Citizens — Sparking a 5% Market Plunge Before Clarification

A comment by Korea's top presidential policy adviser about taxing AI profits to pay citizens sent the Kospi into a 5% nosedive before he walked it back, revealing...

Read more

Microsoft Targeted a $92 Billion Return on Its $13 Billion OpenAI Bet

by Team Lumida
7 days ago
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Court documents in the Musk v. OpenAI trial reveal Microsoft modeled a $92 billion return on its early AI investment — a target that looks conservative given OpenAI's...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Meta’s Content Moderation Shift: Scale Trumps Twitter-Style Risks

Meta’s Content Moderation Shift: Scale Trumps Twitter-Style Risks

January 17, 2025
S&P 500’s Big Earnings Test: Will Tech Slowdown Derail Gains?

U.S. Stocks Extend Rally Into Holiday Week as Rate-Cut Expectations and AI Optimism Lift Markets

November 27, 2025
Hollywood Disrupted: Streaming Giants Seek New Compensation Models

Hollywood Disrupted: Streaming Giants Seek New Compensation Models

May 17, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018